Startup Altido Bio is trying to commercialize CAR-T cell therapy to treat glioblastoma tumors, which are almost always fatal[1]. Glioblastoma is the most aggressive brain tumor for which standard treatment includes surgery, radiotherapy and chemotherapy with temozolomide for a total of nine months, but recurrences are common[6]. CAR-T therapy, successful in leukemias and lymphomas, is being adapted to solid tumors such as glioblastoma by modifying the patient's T lymphocytes to attack specific tumor cell proteins[2][5]. A study published in the New England Journal of Medicine tested CAR-T targeting both the mutated EGFRvIII variant and the normal form of EGFR, present in many glioblastomas[1]. After a single intraventricular infusion in three adult patients, rapid and significant radiographic regression of tumors occurred in all [1]. In one patient, the tumor reappeared after a month, in another, it did not show progression for seven months, and in the remaining three patients (out of a total of six), the tumors did not recur within six months[1]. Initial results have shown preliminary safety, bioactivity and encouraging efficacy, but require confirmation in a larger number of patients and longer follow-up[1]. Other approaches include dual CAR-T against EGFR and IL13Rα2 (expressed in 60% and 75% of glioblastomas) or against the P32 protein in preclinical tests in animal models[2][3][5].